Skip to content
DraconiticResearch
Search Sources API
194,230 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY 4.0JAMA Network Open

Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients

  • Victoria G. Hall1,2,3
  • Adrian A. Alexander1,2,4,5
  • Madeline R. Kern-Smith3
  • Faranak Mavandadnejad3
  • Sarayna Bala3,6
  • Xiaoqing Dang7,8
  • Rujun Kang7,8
  • Sapna Humar1
  • Poramed Winichakoon1,9
  • Rochelle Johnstone1
  • Ailya Salman10
  • Meghan Aversa2,3,11
6 more authors
  • Igor Novitzky-Basso2,12
  • Roni Bitterman1,3
  • Pascal M. Lavoie7,8
  • Deepali Kumar1,2,3,13
  • Jonas Mattsson2,12,14
  • Victor H. Ferreira3,6,13
14 affiliations
  1. 1Division of Infectious Diseases, University Health Network, Toronto, Ontario, Canada
  2. 2Temetry Faculty of Medicine, Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  3. 3Ajmera Transplant Centre Research Institute, University Health Network, Toronto, Ontario, Canada
  4. 4Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
  5. 5Transplant Infectious Diseases Program, Foothills Medical Centre, Alberta Health Services, Calgary, Alberta, Canada
  6. 6Temetry Faculty of Medicine, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  7. 7BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
  8. 8Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada
  9. 9Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  10. 10Clinical Research Unit, University Health Network, Toronto, Ontario, Canada
  11. 11Division of Respirology, University Health Network, Toronto, Ontario, Canada
  12. 12Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network, Toronto, Ontario, Canada
  13. 13Temetry Faculty of Medicine, Institute of Medical Sciences, University of Toronto, Toronto, Ontario, Canada
  14. 14Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, University Health Network, and University of Toronto, Toronto, Ontario, Canada
Open at sourceDOICite

Abstract

This nonrandomized clinical trial examines humoral and cell-mediated immunity and longer-term safety following vaccination for respiratory syncytial virus (RSV) among recipients of lung transplant and allogeneic hematopoietic cell transplant.

Related

  1. Immunogenicity of sequential conjugate and non-conjugate pneumococcal vaccination in dialysis patients and kidney transplant recipients: a 12-month serological follow-up
    Sophie Novelli, Aimé Nun, Antoine Cases +3
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossrefEurope PMC
  2. Evaluating the 2023 safety-net kidney policy: Eligibility and outcomes of heart transplant recipients in the United States.
    Hedwig Zappacosta, Malini Daniel, Natalie Tan +4
    JTCVS openPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  3. Efficacy and Safety of Adoptive BK Polyomavirus-Reactive T-Cell Therapy for Active Infection or Disease in Transplant Recipients: A Systematic Review.
    Felix Bratosin, Shiva Charana Kodimala, Alexei Croitor +2
    VirusesPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Association of eplet mismatch load and allograft injury in kidney transplant recipients
    Clinical kidney journalPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. The Tell-Tale Heart ― Persistent Immune Activation in Histologically Rejection-Free Heart Transplant Recipients ―
    Toshiyuki Ko, Hiroyuki Morita
    Circulation JournalPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{hall2026durability,
  title = {{Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients}},
  author = {Victoria G. Hall and Adrian A. Alexander and Madeline R. Kern-Smith and Faranak Mavandadnejad and Sarayna Bala and Xiaoqing Dang and Rujun Kang and Sapna Humar and Poramed Winichakoon and Rochelle Johnstone and Ailya Salman and Meghan Aversa and Igor Novitzky-Basso and Roni Bitterman and Pascal M. Lavoie and Deepali Kumar and Jonas Mattsson and Victor H. Ferreira},
  journal = {JAMA Network Open},
  year = {2026},
  month = nov,
  doi = {10.1001/jamanetworkopen.2026.41946},
  url = {https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856329},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Durability of Immunity and Safety of RSV Vaccination in High-Risk Transplant Recipients
AU  - Victoria G. Hall
AU  - Adrian A. Alexander
AU  - Madeline R. Kern-Smith
AU  - Faranak Mavandadnejad
AU  - Sarayna Bala
AU  - Xiaoqing Dang
AU  - Rujun Kang
AU  - Sapna Humar
AU  - Poramed Winichakoon
AU  - Rochelle Johnstone
AU  - Ailya Salman
AU  - Meghan Aversa
AU  - Igor Novitzky-Basso
AU  - Roni Bitterman
AU  - Pascal M. Lavoie
AU  - Deepali Kumar
AU  - Jonas Mattsson
AU  - Victor H. Ferreira
PY  - 2026
DA  - 2026/11/06
JO  - JAMA Network Open
DO  - 10.1001/jamanetworkopen.2026.41946
UR  - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2856329
AB  - This nonrandomized clinical trial examines humoral and cell-mediated immunity and longer-term safety following vaccination for respiratory syncytial virus (RSV) among recipients of lung transplant and allogeneic hematopoietic cell transplant.
SN  - 2574-3805
ER  -